Back to search

Article

Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer

2023-11-16

Abstract excerpt

<title>Abstract</title> <p>Recent therapeutic strategies that inhibit the MAPK pathway, a key effector pathway in KRAS-mutated cancers, have attracted considerable attention. Among several molecular-targeted drugs, the RAF/MEK clamp avutometinib (VS-6766 /CH5126766/RO5126766/CKI27) is promising for patients with KRAS-mutated cancers. Although avutometinib monotherapy has shown clinical activity in patients with K...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c6f3b508-7f66-5ea7-b7d1-9774865bce37
DOI
10.21203/rs.3.rs-3558262/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancerDOI 10.21203/rs.3.rs-3558262/v1
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer.Semantic proximity
Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer.Semantic proximity
Avutometinib and Defactinib: First Approval.Semantic proximity
Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination StrategiesSemantic proximity
Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.Semantic proximity
FAK-targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer.Semantic proximity
Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer.Semantic proximity
Coinhibition of the MEK/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancer.Semantic proximity
Synergistic two-step inhibition approach using a combination of trametinib and onvansertib in KRAS and TP53-mutated colorectal adenocarcinomaSemantic proximity
Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.Semantic proximity
FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma.Semantic proximity
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.Semantic proximity
Select a neighboring publication to make it the new centre.